Christopher Yea, CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc. (KALV), sold 2,683 shares at $14.48 ($39K) on 2025-11-18, disclosed to the SEC on 2025-11-19.
Seasonal sale ($39k) by CHIEF DEVELOPMENT OFFICER — this insider has traded KALV in November in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| KALV | SELL | 2026-05-26 | $63K | — | Filing → |
| KALV | SELL | 2026-05-19 | $30K | — | Filing → |
| KALV | SELL | 2026-02-24 | $68K | — | Filing → |